MétaCan
Menu
Back to cohort
Record W4400624727 · doi:10.1016/j.clgc.2024.102161

Regional Differences in Stage III Nonseminoma Germ Cell Tumor Patients Across SEER Registries

2024· article· en· W4400624727 on OpenAlexaff
Cristina Cano Garcia, Francesco Barletta, Stefano Tappero, Mattia Luca Piccinelli, Reha‐Baris Incesu, Simone Morra, Lukas Scheipner, Zhe Tian, Fred Saad, Shahrokh F. Shariat, Sascha Ahyai, Nicola Longo, Derya Tilki, Ottavio De Cobelli, Carlo Terrone, Alberto Briganti, Séverine Banek, Luis A. Kluth, Felix K.‐H. Chun, Pierre I. Karakiewicz

Bibliographic record

VenueClinical Genitourinary Cancer · 2024
Typearticle
Languageen
FieldMedicine
TopicTesticular diseases and treatments
Canadian institutionsMcGill University Health CentreUniversité de Montréal
Fundersnot available
KeywordsMedicineEpidemiologyProportional hazards modelCancer registryInternal medicineSurveillance, Epidemiology, and End ResultsStage (stratigraphy)OncologyHazard ratioCancerGynecologyConfidence interval

Abstract

fetched live from OpenAlex

PurposeWe investigated regional differences in patients with stage III non-seminoma germ cell tumor (NSGCT). Specifically, we investigated differences in baseline patient, tumor characteristics and treatment characteristics, as well as cancer-specific mortality (CSM) across different regions of the United States.MethodsUsing the Surveillance, Epidemiology, and End Results (SEER) database (2004-2018), patient (age, race/ethnicity), tumor (International Germ Cell Cancer Collaborative Group [IGCCCG] prognostic groups) and treatment (systemic therapy and retroperitoneal lymph dissection [RPLND] status) characteristics were tabulated for stage III NSGCT patients, according to 12 SEER registries representing different geographic regions. Multinomial regression models and multivariable Cox regression models testing for cancer-specific mortality (CSM) were used.ResultsIn 3,174 stage III NSGCT patients, registry-specific patient counts ranged from 51 (1.5%) to 1630 (51.3%). Differences across registries existed for age (12-31% for age 40+), race/ethnicity (5-73% for others than non-Hispanic whites), IGCCCG prognostic groups (24-43% vs. 14-24% vs. 3-20%, in respectively poor vs. intermediate vs. good prognosis), systemic therapy (87-96%) and RPLND status (12-35%). After adjustment, clinically meaningful inter-registry differences remained for systemic therapy (84-97%) and RPLND (11-32%). Unadjusted five-year CSM rates ranged from 7.1 to 23.3%. Finally in multivariable analyses addressing CSM, two registries exhibited more favorable outcomes than SEER registry of reference (SEER Registry 12): SEER Registry 4 (Hazard Ratio (HR): 0.36) and SEER Registry 9 (HR: 0.64; both p=0.004).ConclusionWe identified important regional differences in patient, tumor and treatment characteristics, as well as CSM which may be indicative of regional differences in quality of care or expertise in stage III NGSCT management.MicroAbstractOur study analyzed regional variations in patient demographics, tumor prognostics, and treatment outcomes among stage III non-seminoma germ cell tumor patients using the SEER database. It found significant differences in systemic therapy and retroperitoneal lymph dissection rates, as well as cancer-specific mortality across regions, suggesting potential disparities in care quality or expertise.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.733

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.068
GPT teacher head0.398
Teacher spread0.330 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueClinical Genitourinary CancerSame topicTesticular diseases and treatmentsFrench-language works237,207